{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:40:13Z","timestamp":1789400413022,"version":"build-2803163510"},"reference-count":149,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is recognized as a systemic condition that is associated with an increased prevalence of chronic kidney disease (CKD), independent of classical risk factors. This review explores MASLD and metabolic kidney dysfunction, emphasizing lipotoxicity, emerging biomarkers, and liver\u2013kidney fat imaging techniques. Renal fat is discussed as an ectopic lipid depot that may contribute to kidney vulnerability in the same cardiometabolic milieu as MASLD. In this context, lipotoxicity, a phenomenon intensively studied in MASLD, can affect multiple nephron segments, promoting fibrosis and, ultimately, CKD. Hepatokines may support the concept of a liver\u2013kidney metabolic axis, but human data remain limited. Tubular biomarkers show promise for detecting early renal injury, but lack validation in large populations. Hepatic steatosis is quantified through multiple validated imaging techniques such as ultrasound, elastography, and magnetic resonance imaging (MRI). In contrast, renal fat imaging studies are limited and heterogeneous, and still lack standardization. In MASLD, an integrated hepatorenal assessment is warranted to capture the full burden of the disease.<\/jats:p>","DOI":"10.3390\/life15121805","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T10:46:18Z","timestamp":1764067578000},"page":"1805","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["MASLD: Lipotoxicity and Imaging Parallels from Liver Steatosis to Kidney Injury"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9444-0618","authenticated-orcid":false,"given":"Sarmis Marian","family":"S\u0103ndulescu","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa \u0218tefania","family":"Ghiga","sequence":"additional","affiliation":[{"name":"Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Rodica","family":"Tudora\u0219cu","sequence":"additional","affiliation":[{"name":"Department of Medical Semiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7696-3733","authenticated-orcid":false,"given":"Daniela Larisa","family":"S\u0103ndulescu","sequence":"additional","affiliation":[{"name":"Department of Medical Semiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3153-1130","authenticated-orcid":false,"given":"Adrian","family":"Mit\u0103","sequence":"additional","affiliation":[{"name":"Department of Medical Semiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5353-4327","authenticated-orcid":false,"given":"Marinela Cristiana","family":"Urhu\u021b","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Emergency County Hospital of Craiova, 200642 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Citto-Iulian","family":"Taisescu","sequence":"additional","affiliation":[{"name":"Department of Physiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12519-024-00814-1","article-title":"Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: A systematic review and meta-analysis","volume":"20","author":"Lee","year":"2024","journal-title":"World J. Pediatr. WJP"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"EASL, EASD, and EASO (2024). Easl-Easd-Easo clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542.","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"ref_5","unstructured":"GBD 2017 DALYs and HALE Collaborators (2018). Global, regional, and national disability-adjusted life-years (DALYS) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132017: A systematic analysis for the global burden of disease study 2017. Lancet, 392, 1859\u20131922."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: An update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2174\/1381612825666191026113119","article-title":"Risk of kidney dysfunction in NAFLD","volume":"26","author":"Mantovani","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"Kdigo 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Jafar","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102780","DOI":"10.1016\/j.dsx.2023.102780","article-title":"The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis","volume":"17","author":"Agustanti","year":"2023","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.2337\/dc15-1182","article-title":"Fatty liver and chronic kidney disease: Novel mechanistic insights and therapeutic opportunities","volume":"39","author":"Musso","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCRESAHA.116.305360","article-title":"Gut microbiota-dependent trimethylamine n-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease","volume":"116","author":"Tang","year":"2015","journal-title":"Circ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/liv.14419","article-title":"PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings","volume":"40","author":"Mantovani","year":"2020","journal-title":"Liver Int."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yang, T., Yang, B., Yin, J., Hou, C., and Wang, Q. (2025). Targeting insulin resistance and liver fibrosis: CKD screening priorities in MASLD. Biomedicines, 13.","DOI":"10.3390\/biomedicines13040842"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"\u015etefan, A.G., Clenciu, D., Mitrea, A., Vladu, I.M., Protasiewicz-Timofticiuc, D.C., Ro\u015fu, M.M., Maria, D.T., Dinu, I.R., Gheonea, T.C., and Vladu, B.E. (2025). Metabolic syndrome and insulin resistance in Romania. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062389"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000527834","article-title":"Pathological connections between nonalcoholic fatty liver disease and chronic kidney disease","volume":"8","author":"Liu","year":"2022","journal-title":"Kidney Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kushwaha, R., Vardhan, P.S., and Kushwaha, P.P. (2023). Chronic kidney disease interplay with comorbidities and carbohydrate metabolism: A review. Life, 14.","DOI":"10.3390\/life14010013"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pei, K., Gui, T., Li, C., Zhang, Q., Feng, H., Li, Y., Wu, J., and Gai, Z. (2020). Recent progress on lipid intake and chronic kidney disease. BioMed Res. Int., 2020.","DOI":"10.1155\/2020\/3680397"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., and Singh, B.K. (2024). Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1433857"},{"key":"ref_22","first-page":"691","article-title":"MASLD: A systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CEG.S226130","article-title":"Nonalcoholic fatty liver disease and chronic kidney disease: A review of links and risks","volume":"14","author":"Cheung","year":"2021","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Dissayabutra, T., Chuaypen, N., Somnark, P., Boonkaew, B., Udomkarnjananun, S., Kittiskulnam, P., Charoenchittang, P., Prombutara, P., and Tangkijvanich, P. (2025). Characterization of gut dysbiosis and intestinal barrier dysfunction in patients with metabolic dysfunction-associated steatotic liver disease and chronic kidney disease: A comparative study. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-00237-6"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2215\/CJN.0000000732","article-title":"The gut microbiome and the gut-liver-kidney axis in metabolic-associated steatotic liver disease and chronic kidney disease","volume":"20","author":"Caussy","year":"2025","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e16010","DOI":"10.1111\/liv.16010","article-title":"PNPLA3 variation and kidney disease","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.21037\/hbsn-23-558","article-title":"Comparative associations of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease with risk of incident chronic kidney disease: A cohort study","volume":"13","author":"Heo","year":"2024","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/hepr.14226","article-title":"Chronic kidney disease risk associated with metabolic dysfunction-associated steatotic liver disease: A nationwide cohort study in Korea","volume":"55","author":"Kim","year":"2025","journal-title":"Hepatol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: An updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Liu, W., and Sun, X. (2024). Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies. BMC Nephrol., 25.","DOI":"10.1186\/s12882-024-03910-6"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Gurun, M., Brennan, P., Handjiev, S., Khatib, A., Leith, D., Dillon, J.F., and Byrne, C.J. (2024). Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0299507"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e032604","DOI":"10.1161\/JAHA.123.032604","article-title":"Severity and remission of metabolic dysfunction-associated fatty\/steatotic liver disease with chronic kidney disease occurrence","volume":"13","author":"Gao","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.12998\/wjcc.v11.i7.1506","article-title":"Accessory renal arteries\u2014A source of hypertension: A case report","volume":"11","author":"Calinoiu","year":"2023","journal-title":"World J. Clin. Cases"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ren, L., Cui, H., Wang, Y., Ju, F., Cai, Y., Gang, X., and Wang, G. (2023). The role of lipotoxicity in kidney disease: From molecular mechanisms to therapeutic prospects. Biomed. Pharmacother., 161.","DOI":"10.1016\/j.biopha.2023.114465"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00041433-200306000-00008","article-title":"Lipotoxicity: When tissues overeat","volume":"14","author":"Schaffer","year":"2003","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-319-48382-5_8","article-title":"What is lipotoxicity?","volume":"960","author":"Engin","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MNH.0b013e32833aa4ac","article-title":"Renal lipid metabolism and lipotoxicity","volume":"19","author":"Bobulescu","year":"2010","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jhep.2023.01.024","article-title":"An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease","volume":"78","author":"Lee","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"119053","DOI":"10.1016\/j.atherosclerosis.2024.119053","article-title":"Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"400","author":"Maccali","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: Is cd36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2018.04.006","article-title":"CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis","volume":"69","author":"Zhao","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1194\/jlr.M037812","article-title":"CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob\/ob mice","volume":"54","author":"Nassir","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Bieghs, V., Verheyen, F., van Gorp, P.J., Hendrikx, T., Wouters, K., L\u00fctjohann, D., Gijbels, M.J., Febbraio, M., Binder, C.J., and Hofker, M.H. (2012). Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034378"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1053\/jhep.2001.27828","article-title":"Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis","volume":"34","author":"Schneiderhan","year":"2001","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/eci.12192","article-title":"Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease","volume":"44","author":"Crespo","year":"2014","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ramos-Molina, B., Rossell, J., P\u00e9rez-Montes de Oca, A., Pardina, E., Genua, I., Rojo-L\u00f3pez, M.I., Juli\u00e1n, M.T., Alonso, N., Julve, J., and Mauricio, D. (2024). Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1400961"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"14859","DOI":"10.1038\/ncomms14859","article-title":"Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice","volume":"8","author":"Schweiger","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1194\/jlr.R066357","article-title":"Lipotoxic lethal and sublethal stress signaling in hepatocytes: Relevance to nash pathogenesis","volume":"57","author":"Hirsova","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Hajduch, E., Lachkar, F., Ferr\u00e9, P., and Foufelle, F. (2021). Roles of ceramides in non-alcoholic fatty liver disease. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040792"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cmet.2011.11.004","article-title":"Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease","volume":"14","author":"Sunny","year":"2011","journal-title":"Cell Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2022.09.020","article-title":"Mitochondrial alterations in fatty liver diseases","volume":"78","author":"Fromenty","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Radosavljevic, T., Brankovic, M., Samardzic, J., Djureti\u0107, J., Vukicevic, D., Vucevic, D., and Jakovljevic, V. (2024). Altered mitochondrial function in MASLD: Key features and promising therapeutic approaches. Antioxidants, 13.","DOI":"10.3390\/antiox13080906"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Li, X., Chen, W., Jia, Z., Xiao, Y., Shi, A., and Ma, X. (2025). Mitochondrial dysfunction as a pathogenesis and therapeutic strategy for metabolic-dysfunction-associated steatotic liver disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094256"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7570\/jomes23054","article-title":"Mitochondrial quality control: Its role in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"32","author":"Shin","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8900122","DOI":"10.1155\/2021\/8900122","article-title":"Mitochondrial mechanisms of apoptosis and necroptosis in liver diseases","volume":"2021","author":"Chu","year":"2021","journal-title":"Anal. Cell. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ajpath.2023.08.007","article-title":"The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis","volume":"193","author":"Venkatesan","year":"2023","journal-title":"Am. J. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Roy, S., Saha, P., Bose, D., Trivedi, A., More, M., Xiao, S., Diehl, A.M., and Chatterjee, S. (2023). Hepatic NLRP3-derived HSP70 binding to tlr4 mediates MASLD to mash progression upon inhibition of PP2A by harmful algal bloom toxin microcystin, a second hit. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216354"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Meyer, M., Schw\u00e4rzler, J., Jukic, A., and Tilg, H. (2024). Innate immunity and MASLD. Biomolecules, 14.","DOI":"10.3390\/biom14040476"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5483\/BMBRep.2024-0058","article-title":"Neutrophils in MASLD and MASH","volume":"58","author":"Shrestha","year":"2025","journal-title":"BMB Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.cmet.2023.10.009","article-title":"The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease","volume":"35","author":"Sawada","year":"2023","journal-title":"Cell Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e2149641","DOI":"10.1002\/eji.202149641","article-title":"The \u201cdomino effect\u201d in MASLD: The inflammatory cascade of steatohepatitis","volume":"54","author":"Wensveen","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","article-title":"Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease","volume":"2","author":"Moorhead","year":"1982","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Gewin, L.S. (2021). Sugar or fat? Renal tubular metabolism reviewed in health and disease. Nutrients, 13.","DOI":"10.3390\/nu13051580"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"32317","DOI":"10.1074\/jbc.M500801200","article-title":"Diet-induced obesity in C57BL\/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway","volume":"280","author":"Jiang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2147\/JIR.S299083","article-title":"Exposure to high-fat style diet induced renal and liver structural changes, lipid accumulation and inflammation in intact and ovariectomized female rats","volume":"14","author":"Sucedaram","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12986-018-0322-7","article-title":"Dietary pattern and incidence of chronic kidney disease among adults: A population-based study","volume":"15","author":"Asghari","year":"2018","journal-title":"Nutr. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Schelling, J.R. (2022). The contribution of lipotoxicity to diabetic kidney disease. Cells, 11.","DOI":"10.3390\/cells11203236"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2147\/DMSO.S433649","article-title":"The new challenge of obesity\u2014Obesity-associated nephropathy","volume":"17","author":"Hao","year":"2024","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrneph.2017.126","article-title":"CD36 in chronic kidney disease: Novel insights and therapeutic opportunities","volume":"13","author":"Yang","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Xu, W., Zhu, Y., Wang, S., Liu, J., and Li, H. (2024). From adipose to ailing kidneys: The role of lipid metabolism in obesity-related chronic kidney disease. Antioxidants, 13.","DOI":"10.3390\/antiox13121540"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2292753","DOI":"10.1080\/0886022X.2023.2292753","article-title":"CD36 deletion ameliorates diabetic kidney disease by restoring fatty acid oxidation and improving mitochondrial function","volume":"45","author":"Niu","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Panov, A., Mayorov, V.I., and Dikalov, S. (2022). Metabolic syndrome and \u03b2-oxidation of long-chain fatty acids in the brain, heart, and kidney mitochondria. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23074047"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2015","journal-title":"Nat. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Opazo-R\u00edos, L., Mas, S., Mar\u00edn-Royo, G., Mezzano, S., G\u00f3mez-Guerrero, C., Moreno, J.A., and Egido, J. (2020). Lipotoxicity and diabetic nephropathy: Novel mechanistic insights and therapeutic opportunities. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072632"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41420-025-02419-7","article-title":"High-fat diet promotes lipotoxicity in the podocytes of uninephrectomized mice: A targeted lipidomics and kidney podocyte-specific analysis","volume":"11","author":"Oh","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12933-024-02399-5","article-title":"Epicardial and liver fat implications in albuminuria: A retrospective study","volume":"23","author":"Perdomo","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"285","DOI":"10.7150\/ijms.28264","article-title":"Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus","volume":"16","author":"Kang","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2147\/JIR.S410338","article-title":"Expression and significance of KIM-1, NGAL, and HO-1 in patients with acute kidney injury after cardiac valve replacement","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Inflamm. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00467-014-2829-0","article-title":"Determination of early urinary renal injury markers in obese children","volume":"30","author":"Goknar","year":"2015","journal-title":"Pediatr. Nephrol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Rico-Fontalvo, J., Aroca-Mart\u00ednez, G., Daza-Arnedo, R., Cabrales, J., Rodr\u00edguez-Yanez, T., Cardona-Blanco, M., Montejo-Hern\u00e1ndez, J., Rodelo Barrios, D., Pati\u00f1o-Pati\u00f1o, J., and Osorio Rodr\u00edguez, E. (2023). Novel biomarkers of diabetic kidney disease. Biomolecules, 13.","DOI":"10.3390\/biom13040633"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-023-06071-0","article-title":"Body mass index and implications for pediatric kidney health: A cross-sectional study with urinary biomarkers","volume":"39","author":"Gunasekara","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2337\/dc12-1868","article-title":"Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes","volume":"36","author":"Panduru","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2337\/dc10-1392","article-title":"Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients","volume":"34","author":"Sugaya","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"100354","DOI":"10.1016\/j.metop.2025.100354","article-title":"Lipidomics reveals potential biomarkers and pathophysiological insights in the progression of diabetic kidney disease","volume":"25","author":"Guo","year":"2025","journal-title":"Metab. Open"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ekir.2016.08.007","article-title":"Lipidomic signature of progression of chronic kidney disease in the chronic renal insufficiency cohort","volume":"1","author":"Afshinnia","year":"2016","journal-title":"Kidney Int. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ-linking NAFLD and insulin resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Milani, I., Codini, M., Guarisco, G., Chinucci, M., Gaita, C., Leonetti, F., and Capoccia, D. (2024). Hepatokines and MASLD: The GLP1-RAS-FGF21-fetuin-A crosstalk as a therapeutic target. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910795"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Das, S., Chattopadhyay, D., Chatterjee, S.K., Mondal, S.A., Majumdar, S.S., Mukhopadhyay, S., Saha, N., Velayutham, R., Bhattacharya, S., and Mukherjee, S. (2021). Increase in PPAR\u03b3 inhibitory phosphorylation by fetuin-a through the activation of RAS-MEK-ERK pathway causes insulin resistance. Biochim. Biophys. Acta Mol. Basis Dis., 1867.","DOI":"10.1016\/j.bbadis.2020.166050"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Elhoseeny, M.M., Abdulaziz, B.A., Mohamed, M.A., Elsharaby, R.M., Rashad, G.M., and Othman, A.A.A. (2024). Fetuin-a: A relevant novel serum biomarker for non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD): A retrospective case-control study. BMC Gastroenterol., 24.","DOI":"10.1186\/s12876-024-03310-y"},{"key":"ref_95","first-page":"3","article-title":"Systematic review and meta-analysis of circulating fetuin-a levels in nonalcoholic fatty liver disease","volume":"9","author":"Liu","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Vall\u00e9s, P.G., Gil Lorenzo, A.F., Garcia, R.D., Cacciamani, V., Benardon, M.E., and Costantino, V.V. (2023). Toll-like receptor 4 in acute kidney injury. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021415"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Dagher, P.C., Hato, T., Mang, H.E., Plotkin, Z., Richardson, Q.V., Massad, M., Mai, E., Kuehl, S.E., Graham, P., and Kumar, R. (2016). Inhibition of toll-like receptor 4 signaling mitigates microvascular loss but not fibrosis in a model of ischemic acute kidney injury. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050647"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/ndt\/gfl204","article-title":"Fetuin-A and kidney function in persons with coronary artery disease\u2014Data from the heart and soul study","volume":"21","author":"Ix","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3000605221082874","DOI":"10.1177\/03000605221082874","article-title":"Causal association pathways between fetuin-a and kidney function: A mediation analysis","volume":"50","author":"Bassey","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"c233","DOI":"10.1159\/000120209","article-title":"Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease","volume":"108","author":"Caglar","year":"2008","journal-title":"Nephron Clin. Pract."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"iv130","DOI":"10.1093\/ndt\/gft072","article-title":"Association between the body mass index and chronic kidney disease in men and women. A population-based study from Israel","volume":"28","author":"Cohen","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1046\/j.1523-1755.2001.0590041498.x","article-title":"Obesity-related glomerulopathy: An emerging epidemic","volume":"59","author":"Kambham","year":"2001","journal-title":"Kidney Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"sfae065","DOI":"10.1093\/ckj\/sfae065","article-title":"Associations of urinary fetuin-a with histopathology and kidney events in biopsy-proven kidney disease","volume":"17","author":"Tsai","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Musolino, M., Greco, M., D\u2019Agostino, M., Tripodi, L., Misiti, R., Dragone, F., Cianfrone, P., Zicarelli, M., Foti, D.P., and Andreucci, M. (2024). Urinary post-translationally modified fetuin-a (uPTM-FetA) in chronic kidney disease patients with and without diabetic kidney disease. Medicina, 60.","DOI":"10.3390\/medicina60030363"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Welliam, Y., Witarto, B.S., Visuddho, V., Wungu, C.D.K., Budiarto, R.M., Susilo, H., and Multazam, C. (2025). Osteopontin, kidney injury molecule-1, and fetuin-a as prognostic markers of end-stage renal disease: A systematic review and meta-analysis. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0320804"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000534514","article-title":"Urinary fetuin-a fragments predict progressive estimated glomerular filtration rate decline in two independent type 2 diabetes cohorts of different ethnicities","volume":"55","author":"Chuang","year":"2024","journal-title":"Am. J. Nephrol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/ckj\/sfaa176","article-title":"Urinary fetuin-a peptides as a new marker for impaired kidney function in patients with type 2 diabetes","volume":"14","author":"Mischak","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"159","DOI":"10.47162\/RJME.65.2.02","article-title":"The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: A narrative review","volume":"65","author":"Negroiu","year":"2024","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.atherosclerosis.2020.03.009","article-title":"Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease","volume":"299","author":"Tucker","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1210\/jc.2018-02414","article-title":"Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes","volume":"104","author":"Barb","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/ijbs.73936","article-title":"Targeting FGF21 in cardiovascular and metabolic diseases: From mechanism to medicine","volume":"19","author":"Tan","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Kohara, M., Masuda, T., Shiizaki, K., Akimoto, T., Watanabe, Y., Honma, S., Sekiguchi, C., Miyazawa, Y., Kusano, E., and Kanda, Y. (2017). Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0178971"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Lin, Z., Zhou, Z., Liu, Y., Gong, Q., Yan, X., Xiao, J., Wang, X., Lin, S., Feng, W., and Li, X. (2011). Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018398"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40620-018-0550-y","article-title":"Fibroblast growth factor 21 in chronic kidney disease","volume":"32","author":"Suassuna","year":"2019","journal-title":"J. Nephrol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1210\/en.2012-2276","article-title":"Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db\/db mice","volume":"154","author":"Kim","year":"2013","journal-title":"Endocrinology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4103\/0366-6999.226065","article-title":"Protection effect of exogenous fibroblast growth factor 21 on the kidney injury in vascular calcification rats","volume":"131","author":"Shi","year":"2018","journal-title":"Chin. Med. J."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wang, F., Zhang, C., Yao, F., Zhang, B., Zhang, Y., and Sun, X. (2024). FGF21 ameliorates diabetic nephropathy through CDK1-dependently regulating the cell cycle. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1500458"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"155616","DOI":"10.1016\/j.metabol.2023.155616","article-title":"Renoprotective effects of genetically proxied fibroblast growth factor 21: Mendelian randomization, proteome-wide and metabolome-wide association study","volume":"145","author":"Giontella","year":"2023","journal-title":"Metabolism"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/15548627.2023.2259282","article-title":"FGF21 and autophagy coordinately counteract kidney disease progression during aging and obesity","volume":"20","author":"Minami","year":"2024","journal-title":"Autophagy"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"854","DOI":"10.4158\/EP-2018-0568","article-title":"Fatty kidney disease: A new renal and endocrine clinical entity? Describing the role of the kidney in obesity, metabolic syndrome, and type 2 diabetes","volume":"25","author":"Mende","year":"2019","journal-title":"Endocr. Pract."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1161\/HYPERTENSIONAHA.111.175315","article-title":"Fatty kidney, hypertension, and chronic kidney disease: The Framingham heart study","volume":"58","author":"Foster","year":"2011","journal-title":"Hypertension"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Petzold, G. (2022). Role of ultrasound methods for the assessment of NAFLD. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154581"},{"key":"ref_125","first-page":"48","article-title":"Renal parenchymal disease: Histopathologic-sonographic correlation","volume":"54","author":"Rebelo","year":"2008","journal-title":"Rev. Assoc. Medica Bras."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ndt\/gfq522","article-title":"Para- and perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients","volume":"26","author":"Lamacchia","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (cap) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e70123","DOI":"10.1002\/mco2.70123","article-title":"Noninvasive quantification of hepatic steatosis using ultrasound-derived fat fraction (CHESS2303): A prospective multicenter study","volume":"6","author":"Huang","year":"2025","journal-title":"MedComm"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Raphael, H., Klang, E., Konen, E., Leibowitz, A., Frenkel-Nir, Y., Apter, S., and Grossman, E. (2025). Renal fat accumulation assessed by MRI or CT and its association with clinical and metabolic disorders: A systematic imaging review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14124305"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"73","DOI":"10.47162\/RJME.61.1.08","article-title":"MR spectroscopy of the liver\u2014A reliable non-invasive alternative for evaluating non-alcoholic fatty liver disease","volume":"61","author":"Florescu","year":"2020","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1089\/ars.2017.7066","article-title":"Lipid deposition in kidney diseases: Interplay among redox, lipid mediators, and renal impairment","volume":"28","author":"Su","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"ref_133","first-page":"255","article-title":"The role of elastography in non-alcoholic fatty liver disease","volume":"46","author":"Constantinescu","year":"2020","journal-title":"Curr. Health Sci. J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.21037\/qims-24-330","article-title":"Quantitative assessment of renal steatosis in patients with type 2 diabetes mellitus using the iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence imaging: Repeatability and clinical implications","volume":"14","author":"Liu","year":"2024","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Dong, Y., Zhang, Q., Wang, X., Liu, Y., An, Q., Zhang, Z., Hu, L., Lin, L., and Liu, A. (2025). Preliminary quantitative analysis of renal sinus fat dysfunction in t2dm patients using MRI fat fraction and r2* mapping. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1486839"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.kint.2017.03.019","article-title":"Increased body mass index is a risk factor for end-stage renal disease in the Chinese Singapore population","volume":"92","author":"Lew","year":"2017","journal-title":"Kidney Int."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/TCRM.S125480","article-title":"The association of nephrolithiasis with metabolic syndrome and its components: A cross-sectional analysis","volume":"13","author":"Liu","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e27810","DOI":"10.4161\/onci.27810","article-title":"Obesity and renal cancer: Role of adipokines in the tumor-immune system conflict","volume":"3","author":"Gati","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e12860","DOI":"10.1097\/MD.0000000000012860","article-title":"The association between bmi and kidney cancer risk: An updated dose-response meta-analysis in accordance with PRISMA guideline","volume":"97","author":"Liu","year":"2018","journal-title":"Medicine"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Urhut, C.M., Sandulescu, L.D., Streba, L., Iovanescu, V.F., Sandulescu, S.M., and Danoiu, S. (2022). Hepatocellular carcinoma with gastrointestinal involvement: A systematic review. Diagnostics, 12.","DOI":"10.3390\/diagnostics12051270"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4065\/mcp.2010.0336","article-title":"The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis","volume":"85","author":"Streja","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"100570","DOI":"10.1016\/j.jacadv.2023.100570","article-title":"A closer look at ACC\/AHA and ESC guidelines for managing obesity and overweight in adults","volume":"2","author":"Yurista","year":"2023","journal-title":"JACC Adv."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Suki, M., Imam, A., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., and Sackran, J. (2025). SGLT2 inhibitors in MASLD (metabolic dysfunction-associated steatotic liver disease) associated with sustained hepatic benefits, besides the cardiometabolic. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081118"},{"key":"ref_144","first-page":"e91301","article-title":"The effect of statin therapy on liver enzymes and fibrosis progression in patients with coexisting cardiovascular disease and non-alcoholic fatty liver disease (NAFLD)","volume":"17","author":"Khadija","year":"2025","journal-title":"Cureus"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.clnu.2022.08.001","article-title":"Statins\u2019 efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"41","author":"Boutari","year":"2022","journal-title":"Clin. Nutr."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/apt.18042","article-title":"Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures","volume":"60","author":"Vuppalanchi","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (surpass-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Kahn","year":"2021","journal-title":"Lancet"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/12\/1805\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:13:21Z","timestamp":1764069201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/12\/1805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":149,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["life15121805"],"URL":"https:\/\/doi.org\/10.3390\/life15121805","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}